Evidence map›Paper›PMID 40009444›Full record

ArticleBlood2025

Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions.

Emma Lauder, Erik Anders Kiledal, Laure Maneix, Teal Furnholm, Ana Santibanez, Dongchang Zhao, Yaping Sun, Gregory J Dick, Pavan Reddy

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Emma LauderImmunology Program, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-6619-4336
Erik Anders KiledalDepartment of Earth and Environmental Sciences, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-4565-2187
Laure ManeixDan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.ORCID 0000-0003-0044-5395
Teal FurnholmDepartment of Earth and Environmental Sciences, University of Michigan, Ann Arbor, MI.
Ana SantibanezDepartment of Earth and Environmental Sciences, University of Michigan, Ann Arbor, MI.
Dongchang ZhaoDan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
Yaping SunDan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
Gregory J DickDepartment of Earth and Environmental Sciences, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-7666-6288
Pavan ReddyDan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.ORCID 0000-0001-7264-8429

Funding

Metabolomics CoreP01HL149633 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN, TEWARI, MUNEESH · 2020 to 2024
$11.1M
NHLBI NIH HHS P01 HL149633
6 · The paper itself

Abstract

abstractMicrobial dysbiosis and metabolite changes in the gastrointestinal (GI) tract have been linked to pathogenesis and severity of many diseases, including graft-versus-host disease (GVHD), the major complication of allogeneic hematopoietic stem cell transplantation. However, published studies have only considered the microbiome and metabolome of excreted stool and do not provide insight into the variability of the microbial community and metabolite composition throughout the GI tract or the unique temporal dynamics associated with different gut locations. Because such geographical variations are known to influence disease processes, we used a multi-omics approach to characterize the microbiome and metabolite profiles of gut contents from different intestinal regions in well-characterized mouse models of GVHD. Our analysis validated analyses from excreted stool, but importantly, uncovered new biological insights from the microbial and metabolite changes between syngeneic and allogeneic hosts that varied by GI location and time after transplantation. Our integrated analysis confirmed the involvement of known metabolic pathways, including short-chain fatty acid synthesis and bile acid metabolism, and identified additional functional genes, pathways, and metabolites, such as amino acids, fatty acids, and sphingolipids, linked to GI GVHD. Finally, we validated a biological relevance for one such newly identified microbial metabolite, phenyl lactate, that heretofore had not been linked to GI GVHD. Thus, our analysis of the geographic variability in the intestinal microbiome and metabolome offers new insights into GI GVHD pathogenesis and potential for novel therapeutics.

Indexed as

Gastrointestinal MicrobiomeGraft vs Host DiseaseIntestinesMetabolomeAnimalsFemaleHematopoietic Stem Cell TransplantationMiceMice, Inbred C57BL

Identifiers

PMID40009444
PMCPMC12163738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.